INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Core Viewpoint - INmune Bio, Inc. (INMB) has experienced a significant decline of 23.8% over the past four weeks, but it is now positioned for a potential trend reversal as it is in oversold territory, supported by analysts predicting better earnings than previously expected [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2] - INMB's current RSI reading is 27.46, suggesting that the heavy selling pressure may be exhausting itself and a trend reversal could be imminent [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for INMB have increased by 15.7% over the last 30 days, indicating a potential for price appreciation [6] - INMB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential turnaround [7]